Sucraid® is the only FDA-approved enzyme replacement therapy for treating sucrase deficiency due to Congenital Sucrase-Isomaltase Deficiency (CSID). Rizco collaborated with QOL Medical to develop an engaging and informative eDetail microsite that effectively communicates the complexities of this condition to busy healthcare providers.
Sucraid® eDetail
Enhancing CSID Treatment Education for Healthcare Providers
What We Did
- Website Design & Development
- Icon & Illustration Development
- Custom Lottie Animations
Reframing intolerance: a clearer understanding of CSID.
CSID is a rare, inherited disorder that prevents the body from digesting and absorbing sugar properly, leading to Sucrose Intolerance. While lactose and gluten intolerance are widely recognized, CSID remains lesser-known. Sucraid® is the only FDA-approved enzyme replacement therapy specifically designed to address sucrase deficiency in CSID patients.
A digital platform for clear communication.
The Sucraid® eDetail website serves as an educational hub, offering comprehensive and easily digestible information about CSID. Designed to accommodate the fast-paced environment of healthcare providers, the platform covers symptoms, diagnosis, prescribing guidelines, and treatment details, ensuring that key information is accessible and engaging.
Clarifying CSID diagnosis and treatment.
CSID symptoms are often mistaken for other gastrointestinal conditions like IBS. A well-structured brand system ensures healthcare providers have access to clear, thorough information about CSID and its treatment with Sucraid®. The platform educates both patients and medical professionals on identifying CSID, managing symptoms, and accessing appropriate treatment.
Bringing the condition to life through animation.
Animated visual elements enhance understanding by depicting symptoms and treatment in a relatable and engaging way. A custom icon system further simplifies complex medical information, making it approachable for both patients and healthcare providers.
Watery Diarrhea
Bloating
Excess Gas Production
Abdominal Pain
Nausea
Vomiting
A flexible learning system for healthcare providers.
The website provides a user-friendly experience with a clean and intuitive design. It seamlessly integrates informative text and visuals, making complex medical concepts more digestible. Healthcare professionals can easily navigate through details on symptoms, diagnosis, and treatment protocols for CSID.
Illustrating the mechanism of action.
A carefully crafted animated illustration demonstrates how Sucraid® works. As a sucrase enzyme replacement, sacrosidase breaks down sucrose into glucose and fructose, facilitating absorption into the bloodstream from the small intestine. This visual representation simplifies a critical aspect of the treatment process.
Designing clear prescribing information.
The prescribing information (PI) section serves as a step-by-step instructional guide for the safe and effective use of Sucraid®. Custom illustrations clarify dosing, preparation, and administration, enhancing the visual experience throughout the PI, ensuring both patients and caregivers can confidently follow the treatment regimen.
Your words matter.
Rizco is an exceptional design and marketing firm with a highly accessible and collaborative team. For this project, the challenge was to communicate our complex disease state to busy healthcare providers in a comprehensive, inviting, and engaging manner. The project was a significant success as it draws interest and engagement every day. Rizco’s creativity, strategic approach, and attention to detail ensure every project is delivered on time, within budget, and beyond expectations.
Anthony D’Elia
Vice President, Marketing
QOL Medical, LLC
81
In clinical trials, 81% of patients became asymptomatic with Sucraid®.*
*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no GI symptoms for at least 7 of the 10 study days.
